TOTEM-RRMS
TestOsterone TreatmEnt on neuroprotection and Myelin repair in Relapsing Remitting Multiple Sclerosis
What was tested
Treatment tested
- Testosterone
Androgen Receptor agonist
What it measured
Main measures
Binary criterion comparing the success rate in each treatment group, defined by thalamic atrophy less than 0.5% per year and / or a decrease in transverse diffusivity in lesions less than 0.5% per year.
MRI lesionsBrain volume loss
Other measures (1)
Efficiency of treatment by imaging:
Loading reviews and guidelines…
Related trials
- TOTEM-RRMS
Phase 2 · Recruiting
Still running
- Vaginal Estriol in Multiple Sclerosis
Phase 2 / Phase 3 · Completed
Met its main goal
- rhGH in MS
Phase 2 · Completed
No result found
- Estriol-MS
Phase 2 · Completed
Missed its main goal
- Safety and Tolerability of Interferon-Beta-1a and Estropr…
Phase 2 · Status unknown
Result in a paper, not read yet
- Testosterone Treatment for Multiple Sclerosis
Phase 1 / Phase 2 · Completed
Met its main goal
History
- In scope changed from true to false
Started
Apr 2019
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error